DesigneRx Pharmaceuticals, Inc. announced a private placement of 15,000,000 common shares at a price of $1 per share for gross proceeds of $15,000,000 on April 24, 2023. The transaction will include participation from returning investor Polaris Group. The transaction was approved by the board of directors of the company.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
71.4 TWD | -0.70% |
|
-0.97% | -5.56% |
05-15 | Polaris Group Voluntarily Withdraws the Phase III Clinical Trial Protocol for Liver Cancer from the FDA | CI |
05-14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.56% | 1.66B | |
+46.03% | 56.61B | |
-7.57% | 39.62B | |
+36.02% | 39.25B | |
-9.38% | 28.28B | |
+12.31% | 26.44B | |
-16.44% | 20.12B | |
+30.97% | 12.51B | |
+28.69% | 12.48B | |
-0.23% | 12.2B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- DesigneRx Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from Polaris Group